Kilitch Drugs Limited, a BSE and NSE-listed pharmaceutical company, has reported a 222% year-on-year (YoY) growth in consolidated profit after tax (PAT) for Q3 FY25, reaching ₹5.61 crore, compared to ₹1.74 crore in the same period last year.
The company’s consolidated revenue from operations rose 77% YoY to ₹56.17 crore, up from ₹31.79 crore in Q3 FY24. This growth is attributed to consistent demand across global markets.
On a standalone basis, the company’s PAT grew 25%, while revenue increased 56% YoY, reaching ₹6.88 crore and ₹46.51 crore, respectively, in Q3 FY25.
For the nine-month period ending December 2024 (9MFY25), Kilitch Drugs recorded a 42% YoY increase in net profit to ₹19.78 crore, compared to ₹13.93 crore in 9MFY24. Revenue for the period climbed 35% YoY to ₹125.28 crore from ₹92.46 crore in the previous year.
Kilitch Drugs continues to focus on sustainable growth and strong returns, leveraging its expertise in Parenteral, Injectables, Oral Solids, and Effervescent pharmaceutical solutions.
